Capmatinib Drug Encyclopedia

Capmatinib (Capmatinib) is an oral, small molecule inhibitor of the mesenchymal epithelial transition (MET) factor tyrosine kinase receptor that blocks the binding of its ligand hepatocyte growth factor (HGF), which normally activates signaling pathways related to cell proliferation, motility, and invasion.

The MET gene is mutated or overexpressed in a variety of human cancers, including lung, liver, breast, and ovarian cancer, leading to uncontrolled cell growth and proliferation. Capmatinib has potent activity against selected mutant forms of the MET receptor, including variants resulting from exon 14 skipping, and has been found to inhibit cancer cell growth in multiple tissue culture and animal models of MET dysregulated cancers. In a moderately large open-label trial, capmatinib was found to produce objective responses in 41% of patients with refractory metastatic NSCLC harboring MET mutations and in a higher proportion of treatment-naïve subjects.

Capmatinib was approved in the United States in 2020 for the treatment of adults with NSCLC with mutations that cause MET exon 14 skipping, the first oncology drug approved for this indication. The presence of MET mutations in other forms of cancer is still being evaluated.

Capmatinib is available as 150 mg and 200 mg tablets Tabecta. The recommended dose is 400 mg orally twice daily until disease progression or unacceptable toxicity.

Capmatinib side effects are common, occurring in nearly all patients treated with capmatinib and resulting in the need for dose adjustment or discontinuation in approximately one-quarter of treated patients. Common side effects include edema, nausea and vomiting, anorexia, diarrhea or constipation, musculoskeletal pain, fatigue, fever, cough, dyspnea, and rash. Uncommon but potentially serious adverse events include pneumonitis, interstitial lung disease, hepatotoxicity, photosensitivity, allergic reactions, and embryo-fetotoxicity.

Patients are temporarily unable to purchase capmatinib directly in domestic hospital pharmacies because it is not yet available in the country. It is understood that capmatinib is sold in the European market asIt is sold in the specification of 200mg and 120 tablets, and the price of a box is about 57,000 yuan; in Hong Kong, China, the specification is 200mg and 60 tablets, and the price of a box is about 35,000 yuan. In addition, there are also various versions of capmatinib in Laos, with 56 pills per box and the price ranges from 3,000 to 4,000 yuan. If the patient has more questions about capmatinib, please consult the Yade medical consultant for more information.